Codexis, Inc. (CDXS): Price and Financial Metrics

Codexis, Inc. (CDXS): $3.49

0.02 (-0.57%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add CDXS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#218 of 365

in industry

CDXS Price/Volume Stats

Current price $3.49 52-week high $4.91
Prev. close $3.51 52-week low $1.45
Day low $3.45 Volume 447,800
Day high $3.72 Avg. volume 620,274
50-day MA $3.22 Dividend yield N/A
200-day MA $2.56 Market Cap 245.36M

CDXS Stock Price Chart Interactive Chart >

CDXS POWR Grades

  • CDXS scores best on the Quality dimension, with a Quality rank ahead of 46.36% of US stocks.
  • The strongest trend for CDXS is in Quality, which has been heading down over the past 26 weeks.
  • CDXS ranks lowest in Stability; there it ranks in the 4th percentile.

CDXS Stock Summary

  • With a year-over-year growth in debt of -55.49%, CODEXIS INC's debt growth rate surpasses merely 4.37% of about US stocks.
  • Over the past twelve months, CDXS has reported earnings growth of 162.92%, putting it ahead of 92.92% of US stocks in our set.
  • Revenue growth over the past 12 months for CODEXIS INC comes in at -44.27%, a number that bests merely 5.76% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CODEXIS INC are PSNL, EYPT, MX, PALI, and SAGE.
  • CDXS's SEC filings can be seen here. And to visit CODEXIS INC's official web site, go to www.codexis.com.

CDXS Valuation Summary

  • In comparison to the median Healthcare stock, CDXS's price/sales ratio is 30.95% lower, now standing at 2.9.
  • CDXS's EV/EBIT ratio has moved up 21.5 over the prior 167 months.

Below are key valuation metrics over time for CDXS.

Stock Date P/S P/B P/E EV/EBIT
CDXS 2023-12-29 2.9 2.3 -2.6 -1.9
CDXS 2023-12-28 3.0 2.4 -2.7 -2.0
CDXS 2023-12-27 3.2 2.6 -2.9 -2.2
CDXS 2023-12-26 3.1 2.5 -2.8 -2.1
CDXS 2023-12-22 2.9 2.4 -2.7 -2.0
CDXS 2023-12-21 2.9 2.3 -2.6 -1.9

CDXS Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 19.11%.
  • Its 2 year net cashflow from operations growth rate is now at -70.77%.
  • Its 5 year net cashflow from operations growth rate is now at -70.53%.
CDXS's revenue has moved up $89,778,000 over the prior 70 months.

The table below shows CDXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 138.59 11.284 -33.592
2022-09-30 132.717 7.027 -31.178
2022-06-30 135.016 -12.899 -18.942
2022-03-31 122.063 -19.013 -20.567
2021-12-31 104.754 -14.267 -21.279
2021-09-30 101.287 -16.419 -15.009

CDXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXS has a Quality Grade of C, ranking ahead of 53.6% of graded US stocks.
  • CDXS's asset turnover comes in at 0.423 -- ranking 65th of 89 Chemicals stocks.
  • NGVT, GPP, and IFF are the stocks whose asset turnover ratios are most correlated with CDXS.

The table below shows CDXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.423 0.782 -0.333
2021-03-31 0.406 0.787 -0.370
2020-12-31 0.424 0.801 -0.359
2020-09-30 0.461 0.831 -0.313
2020-06-30 0.479 0.819 -0.220
2020-03-31 0.457 0.796 -0.237

CDXS Price Target

For more insight on analysts targets of CDXS, see our CDXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.50 Average Broker Recommendation 1.31 (Strong Buy)

Codexis, Inc. (CDXS) Company Bio


Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.


CDXS Latest News Stream


Event/Time News Detail
Loading, please wait...

CDXS Latest Social Stream


Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insu

Yahoo | December 27, 2023

Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company

Codexis, Inc. ( NASDAQ:CDXS ) shares have continued their recent momentum with a 41% gain in the last month alone...

Yahoo | December 18, 2023

Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?

Codexis, Inc. ( NASDAQ:CDXS ), might not be a large cap stock, but it received a lot of attention from a substantial...

Yahoo | December 15, 2023

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymesREDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global excl

Yahoo | December 13, 2023

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the preparative-scale manufacture o

Yahoo | December 13, 2023

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo -6.18%
3-mo 14.43%
6-mo 84.66%
1-year -11.42%
3-year -83.43%
5-year -83.00%
YTD 14.43%
2023 -34.55%
2022 -85.10%
2021 43.24%
2020 36.52%
2019 -4.25%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!